These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33307042)

  • 1. Challenges for Cell-Based Medicinal Products From a Pharmaceutical Product Perspective.
    Jere D; Sediq AS; Huwyler J; Vollrath I; Kardorff M; Mahler HC
    J Pharm Sci; 2021 May; 110(5):1900-1908. PubMed ID: 33307042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry.
    Brown H; Mahler HC; Mellman J; Nieto A; Wagner D; Schaar M; Mathaes R; Kossinna J; Schmitting F; Dreher S; Roehl H; Hemminger M; Wuchner K
    PDA J Pharm Sci Technol; 2017; 71(2):147-162. PubMed ID: 27789803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Physical Container Closure Integrity Test Methods and Artificial Leak Methodologies.
    Peláez SS; Mahler HC; Herdlitschka C; Wertli T; Kahl M; Koulov A; Matter A; Singh SK; Widmer M; Germershaus O; Mathaes R
    PDA J Pharm Sci Technol; 2019; 73(3):220-234. PubMed ID: 30651337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation of Cell-Based Medicinal Products: A Question of Life or Death?
    Hoogendoorn KH; Crommelin DJA; Jiskoot W
    J Pharm Sci; 2021 May; 110(5):1885-1894. PubMed ID: 32649938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing Container Closure Integrity and Aesthetics for a Robust Aseptic or Sterile Vial Packaging System.
    Oni Y; Song X; Schrader M; Kulshrestha A; Franck J; Asselta R; Flores-Crespo C; Mantri RV
    PDA J Pharm Sci Technol; 2019; 73(6):572-587. PubMed ID: 31101708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Container Closure System Integrity for Storage of Frozen Drug Products: Impact of Capping Force and Transportation.
    Nieto A; Roehl H; Adler M; Mohl S
    PDA J Pharm Sci Technol; 2018; 72(6):544-552. PubMed ID: 29853608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality.
    Das TK; Sreedhara A; Colandene JD; Chou DK; Filipe V; Grapentin C; Searles J; Christian TR; Narhi LO; Jiskoot W
    J Pharm Sci; 2022 Apr; 111(4):868-886. PubMed ID: 34563537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulated Leaching (Migration) Study for a Model Container-Closure System Applicable to Parenteral and Ophthalmic Drug Products.
    Jenke D; Egert T; Hendricker A; Castner J; Feinberg T; Houston C; Hunt DG; Lynch M; Nicholas K; Norwood DL; Paskiet D; Ruberto M; Smith EJ; Holcomb F; Markovic I
    PDA J Pharm Sci Technol; 2017; 71(2):68-87. PubMed ID: 27974627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-destructive vacuum decay method for pre-filled syringe closure integrity testing compared with dye ingress testing and high-voltage leak detection.
    Simonetti A; Amari F
    PDA J Pharm Sci Technol; 2015; 69(1):108-22. PubMed ID: 25691719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying the Vial Capping Process: Residual Seal Force and Container Closure Integrity.
    Ovadia R; Streubel A; Webb-Vargas Y; Ulland L; Luemkemann J; Rauch K; Eder J; Lam P; Tegoulia V; Maa YF
    PDA J Pharm Sci Technol; 2019; 73(1):2-15. PubMed ID: 29954924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Container-content compatibility studies: a pharmaceutical team's integrated approach.
    Laschi A; Sehnal N; Alarcon A; Barcelo B; Caire-Maurisier F; Delaire M; Feuilloley M; Genot S; Lacaze C; Pisarik L; Smati C
    PDA J Pharm Sci Technol; 2009; 63(4):285-93. PubMed ID: 20088243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk of contamination of sterile parenteral products via ready-to-use closure components.
    Curry W; Conway S; Goodfield C; Miller K; Mueller RL; Polini E
    AAPS PharmSciTech; 2010 Dec; 11(4):1572-9. PubMed ID: 21057904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case study demonstrating the migration of diethyl phthalate from an ancillary component to the drug product.
    Singh G; Gollapalli R; Blinder A; Gallo F; Patel M
    J Pharm Biomed Anal; 2019 Feb; 164():574-580. PubMed ID: 30466025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introducing the Alba® Primary Packaging Platform. Part 2: Inorganic Extractables Evaluation.
    Chillon A; Zuccato D
    PDA J Pharm Sci Technol; 2019; 73(3):235-246. PubMed ID: 30651335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.